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p53 is one of the most important tumor suppressor genes involved in human carcinogenesis. Although
downstream targets of p53 and their biologic functions in cancer cells have been extensively investigated, it is still
far from the full understanding. Here, we demonstrate that Late Cornified Envelope Group I (LCE1) genes, which
are located in the LCE gene clusters encoding multiple well-conserved stratum-corneum proteins, are novel
downstream targets of p53. Exogenous p53 overexpression using an adenoviral vector system significantly
enhanced the expression of LCE1 cluster genes. We also observed induction of LCE1 expressions by DNA
damage, which was caused by treatment with adriamycin or UV irradiation in a wild-type p53-dependent manner.
Concordantly, the induction of LCE1 by DNA damage was significantly attenuated by the knockdown of p53.
Among predicted p53-binding sites within the LCE1 gene cluster, we confirmed one site to be a p53-enhancer
sequence by reporter assays. Furthermore, we identified LCE1 to interact with protein arginine methyltransferase
5 (PRMT5). Knockdown of LCE1 by specific small interfering RNAs significantly increased the symmetric
dimethylation of histone H3 arginine 8, a substrate of PRMT5, and overexpression of LCE1F remarkably decreased
its methylation level. Our data suggest that LCE1 is a novel p53 downstream target that can be directly
transactivated by p53 and is likely to have tumor suppressor functions through modulation of the PRMT5 activity.
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p53 is the most frequently mutated tumor suppressor gene involved
in human cancers [1,2]. Its tetramer protein product can activate the
transcription of a number of target downstream genes and mediate a
variety of biologic functions through the transcriptional regulation of
those targets [3]. To elucidate the critical roles of p53 in human
carcinogenesis, we and others have attempted to identify p53 target
genes through multiple approaches. We have mainly applied the
expression profile analysis after the exogenous introduction of wild-
type p53 into cancer cells using the adenovirus vector system and
identified more than 50 p53 downstream candidate genes [4]. Among
them, we have performed the functional analysis of more than a dozen
of target genes including p53R2, p53AIP1, and p53RDL1 [5–8].
Here, we report the characterization of the Late Cornified Envelope
Group I (LCE1) as a novel downstream target of p53.The LCE clusters contain multiple well-conserved genes encoding
stratum-corneum proteins [9,10] and are located on chromosome
1q21 in a region called as the epidermal differentiation complex
[11,12]. This region is enriched for genes, which are expressed during
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small proline-rich protein genes, and the LCE genes [9,13]. In mice,
members in the LCE1 group are expressed in the relatively late stage
of epithelial development and incorporated into the cornified
envelope through cross-linking by transglutaminases [10]. In
addition, real-time quantitative polymerase chain reaction (qPCR)
analysis demonstrated that human LCE1 and LCE2 genes were
primarily expressed in skin, whereas LCE4 and LCE5 gene
expressions were undetectable in any human tissues examined [9].
In general, physiological functions of LCE proteins, especially their
involvement in human cancer are still largely unknown.
Protein arginine methyltransferases (PRMTs) constitute of a large
family of enzymes having the arginine methyltransferases activity
responsible for catalyzing the formation of monomethyl arginine,
asymmetric dimethyl arginine, and symmetric dimethyl arginine
(SDMA) [14]. PRMT5 is one of the most well-characterized family
members with SDMA activity and catalyzes formation of SDMA in
proteins with a glycine and arginine-rich motif [15]. PRMT5 was
reported to regulate various cellular functions including apoptosis,
Golgi structure, pluripotency, cell growth, and snRNP biosynthesis
[16–18]. One important key marker of the PRMT5 activity is the
symmetrical dimethylation of histone 3 arginine 8 (H3R8me2s) level.
Through hypermethylation of histone H3R8 around the promoter
regions, PRMT5 could cause the transcriptional silencing of cell cycle
regulator genes [19,20]. Since overexpression of PRMT5 has been
reported in various types of human cancer, including melanoma,
leukemia, lymphoma, glioma, as well as ovarian, breast, prostate, and
lung cancers [16,21–23], this enzyme is considered as a good
molecular target for development of novel cancer therapy [16].
In the present study, we demonstrate that LCE is a novel direct
target of p53, can interact with PRMT5, and might modulate histone
H3 methylation by PRMT5. This mechanism may be important for
the interplay of two important cancer-related genes, p53 and
PRMT5, and our findings could indicate a possible role of LCE1 in
human carcinogenesis.
Materials and Methods
Microarray Analysis
Replication-deficient recombinant adenovirus designed to express
wild-type p53 (Ad-p53) or LacZ (Ad-LacZ) was generated and purified,
as previously described [5,24].Microarray analysis was then carried out as
previously described [1,4,24]. In brief, poly(A)+ RNAswere isolated from
U373MG cells at different time points after infection with Ad-p53 or Ad-
LacZ. Each RNA sample was labeled and hybridized to a microarray
consisting of 36,864 genes or Expressed Sequence Tags (ESTs) (http://
www.ncbi.nlm.nih.gov/geo/index.cgi, Accession No. GSE14953).
Cell Culture and Transfection
Human cell lines, U373MG (glioblastoma),H1299 (lung carcinoma),
and Human Embryonic Kidney 293T (HEK293T), were purchased
from American Type Culture Collection (ATCC, Manassas, VA).
HCT116 p53−/− and HCT116 p53+/+ cell lines were obtained from Dr
Bert Vogelstein (Johns Hopkins University, Baltimore, MD). U373MG
glioblastoma cells and H1299 lung cancer cells were infected with Ad-
p53 or Ad-LacZ at various multiplicity of infection (MOI) conditions
and incubated at 37°C until the time of harvest. HEK293T cells were
transfected with HA-Mock (empty vector of pCAGGSnHC) or HA-
LCE1F (pCAGGSnHC-LCE1F) using FuGENE6. For protein-proteininteraction experiments, HEK293T cells were transfected with HA-
Mock or HA-LCE1F and FLAG-Mock or FLAG-PRMT5 using
FuGENE6. To examine the co-localization, HCT116 p53+/+ cells
were transfected by HA-Mock or HA-LCE1F using FuGENE6. For the
gene reporter assay, U373MG (mutated p53) andH1299 (p53 null) cells
were transfected with a reporter plasmid and either a Mock empty vector
of pcDNA3.1+ or a wild-type p53 expression pcDNA3.1+ vector in
combination with a pRL-CMV vector using FuGENE6 [25,26]. Small
interfering RNAs (siRNAs) that were commercially synthesized by
Sigma-Aldrich (St Louis, MO) were transfected with Lipofectamine
RNAiMAX reagent (Life Technologies, Carlsbad, CA). Two siRNA
oligonucleotides of LCE1A-F were designed to target the region
commonly conserved among LCE1A-F. Sequences of oligonucleotides
are shown in Table W1. Western blot or real-time qPCR was applied to
validate the efficiency of overexpression or knockdown experiments.
DNA-Damaging Treatments
Cells were seeded 24 hours before treatment. When cells reached
60% to 70% confluency, cells were incubated with 1 μg/ml adriamycin
for 2 hours followed by further incubation of the drug-free medium.
Then, the cells were harvested at different time points as indicated in the
figure legends. For UV irradiation (UVR) experiments, the cells were
washed twice with phosphate-buffered saline (PBS) and exposed to UV
rays at different doses using XL-1500 Spectrolinker (Spectronics,
Westbury, NY; peak emission, 254 nm). Cells were harvested 36 hours
after UVR treatment.
Real-Time qPCR
Total RNA was isolated from cultured cells using RNeasy mini-spin
column kits (Qiagen, Hilden, Germany) according to the manufacturer’s
procedure. cDNAs were synthesized with the SuperScript Pre-
amplification System (Life Technologies). Real-time qPCR was
conducted using the SYBR Green I Master on the LightCycler 480
(Roche Applied Science, Mannheim, Germany) according to the
manufacturer’s instructions. The primer sequences used in this
manuscript are shown in Tables W1 and W2. Primers for LCE1A,
LCE1C, LCE1E, and LCE1F were described previously [9]. Primers for
LCE1B, LCE1D LCE3A, LCE3B, LCE3C, LCE4A, XP33, and C1orf45
genes were designed by us. Except LCE1D, the specificity of all primers
was confirmed by DNA sequencing of amplicons. For graphic
representation of transcript data, all expression of target genes was
shown relative to the housekeeping gene β2-microglobulin expression in
the same sample.
Prediction of Putative p53-Binding Sites
DNA sequences of an entire genomic region of LCE1 including
10 kb of the 5′ upstream sequence were downloaded from the
University of California Santa Cruz (UCSC) website (http://genome.
ucsc.edu/), and the putative p53-binding sites (p53BSs) were screened
according to the following criteria; at least 80% matched with the 20
nucleotides of consensus sequence RRRCWWGYYY__RRRCWW-
GYYY (R, purine; W, A, or T; Y, pyrimidine); we started the screening
of 11 consensus sequences without any spacers between the two halves
of p53BSs (Figure W1) and confirmed one site that was likely to be a
direct p53-binding sequence.Gene Reporter Assay
DNA fragments including each of the potential p53BSs of the
LCE1 gene cluster were amplified by KOD-Plus-DNA polymerase
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(pGL3-pro) vector. The primers for amplification are indicated in Table
W1. To make a series of mutant vectors, a point mutation “T” was
inserted into the site of the fourth and the fourteenth nucleotide “C”
and into the seventh and the seventeenth nucleotide “G” of the
consensus p53-BS using the KOD-Plus-Mutagenesis Kit (Toyobo).
Since a functional p53BS is known in the Fas promoter region, a wild-
type Fas promoter construct, pGL3-Fas, was used as a positive control.
U373MG (mutated p53) andH1299 (p53 null) cells were plated in 12-
well culture plates (5 × 104 cells per well) 24 hours before co-
transfection of 125 ng of a reporter plasmid and either 125 ng of a
Mock vector or a wild-type p53 expression vector in combination with
25 ng of a pRL-CMV vector. Cells were rinsed with PBS 36 hours after
transfection and lysed in 250 μl of lysis buffer. Twenty microliters and
5 μl of lysates from U373MG and H1299, respectively, were
sequentially measured using the PGD-S Dual Luciferase assay system
following the manufacturer’s procedure (Toyo Ink, Tokyo, Japan). The
firefly luciferase value was normalized by the Renilla luciferase activity.
Expression Plasmid Construction
An entire coding sequence of PRMT5 was amplified using cDNA
generated from mRNA of HEK293T cells and cloned into
pCAGGSn3FC (PRMT5) vector. The entire coding sequences of
LCE1A-F were amplified by the use of cDNA generated from
mRNA that was extracted from HCT116 p53+/+ cells after 70 J/m2
of UVR treatment. Due to unknown reasons, we have been
unsuccessful in cloning the LCE1D cDNA. An HA-epitope tag was
placed at the C-terminus of the pCAGGSnHC vector and three-
tandem FLAG epitope tags were placed at the C-terminus of the
pCAGGSn3FC vector. The DNA sequences of expression constructs
for LCE1 (pCAGGSnHC-LCE1) and PRMT5 (pCAGGSn3FC-
PRMT5) were confirmed by DNA sequencing using ABI PRISM
3730XL Genetic Analyzer (Life Technologies).
Antibodies
The following primary antibodies were deployed: rabbit anti-HA
(Y-11; Santa Cruz Biotechnology, Santa Cruz, CA; dilution used in
WB: 1:1000), rabbit anti-PRMT5 (07-415; Millipore, Billerica, MA;
dilution used in WB: 1:1000, ICC: 1:400), rabbit anti-p53 (sc6243,
Santa Cruz; dilution used in WB: 1:1000), mouse anti-p53 [Ab-1,
Calbiochem, San Diego, CA, dilution used in chromatin immuno-
precipitation (ChIP): 1:100], rabbit anti-H3R8me2s (ab130740,
Abcam, Cambridge, United Kingdom; dilution used in Western blot
(WB): 1:1000), mouse anti–α-tubulin (clone DM1A, Millipore;
dilution used in WB: 1:1000), rat anti-HA (3F10, Roche; dilution
used in Immunocytochemistry (ICC): 1:800), and anti-FLAG
(F7425, Sigma-Aldrich; dilution used in ICC: 1:1000).
Immunocytochemistry
Forty-eight hours after transfection with HA-Mock (empty vector
of pCAGGSnHC) or pCAGGSnHC-HA-LCE1F into HEK293T or
HCT116 p53+/+ cells in four-well chambers, the cells were fixed by
1.7% formaldehyde or 4% paraformaldehyde in PBS and perme-
abilized with 0.2%Triton X-100 in PBS. After covering with blocking
solution (3% BSA in 0.2% Triton X-100) for 1 hour at room
temperature, cells were incubated with a rat anti-HA antibody and a
rabbit PRMT5 antibody overnight under humidified atmosphere at
4°C. Further, the cells were stained with fluorescence-conjugated
secondary antibodies and then counterstained with 4′,6-diamidino-2-phenylindole (DAPI) in VECTASHIELD Mounting Media
(HT1200; Vector Laboratories, Burlingame, CA).
Immunoprecipitation and Mass-Spectrometric Analysis
Forty-eight hours after transfection with HA-Mock or HA-
LCE1F, HEK293T cells were lysed in lysis buffer [50 mM Tris-
HCl (pH 8.0), 0.4% NP-40, and 150 mM NaCl] containing
Protease Inhibitor Cocktail Set III (Calbiochem). Whole-cell lysates
were pre-cleared by incubation with normal mouse IgG (sc2025,
Santa Cruz Biotechnology) and recombinant protein G-sepharose 4B
(Life Technologies) at 4°C for 1 hour, followed by incubation with
anti-HA agarose (A2095, Sigma-Aldrich) overnight. The proteins
were separated in Mini-PROTEAN 5% to 20% gradient sodium
dodecyl sulfate–polyacrylamide gel electrophoresis precast gels (Bio-
Rad Laboratories, Hercules, CA) and stained with the silver-staining
kit (Life Technologies). Protein bands that were specifically
observed in the cell extracts transfected with HA-LCE1F compared
with Mock were excised and analyzed by liquid chromatography–
tandem mass spectrometry as previously described [27]. For the co-
immunoprecipitation experiments, HEK293T cells were co-transfected
with HA-LCE1F and FLAG-PRMT5 or FLAG-Mock as a control. An
HA pull-down experiment is exactly the same as mentioned above. As
for FLAG pull-down experiment, whole-cell lysates were pre-cleared
by incubation with normal mouse IgG (sc2025, Santa Cruz
Biotechnology) and recombinant protein G-sepharose 4B (Life
Technologies) at 4°C for 1 hour, followed by incubation with mouse
anti-FLAG M2 agarose (F3165, Sigma-Aldrich) overnight. Rat anti-
HA (3 F10, Roche) and rabbit anti-Flag (F7425, Sigma-Aldrich)
antibodies were used for Western blot. For the histone methylation
analysis, histones were extracted by the histone purification mini kit
(40026, Active Motif, Carlsbad, CA) following the manufacturer’s
procedure strictly.
ChIP Assay
ChIP assays were performed using ChIP Assay kit (17-295; Millipore)
according to the manufacturer’s protocol [28]. Briefly, HCT116 p53+/+
cells were treated with 1 μg/ml adriamycin for 2 hours, and cells were
cultured in the drug free-medium for 24 hours. Then, cells were
harvested and the fragment of p53 and chromatin complexes was
immnoprecipitated with an anti-p53 antibody (Ab-1, Calbiochem). After
DNA fragments bound to p53 were eluted out, an aliquot was subjected
to real-time qPCRs. Protein A agarose/Salmon Sperm DNA (16-157;
Millipore) was used as a negative control. Primers were designed to
amplify the region containing the p53BS2-binding site, and their
sequence information is shown in Table W1.
Results
Identification of a Novel p53 Downstream Target
We had previously performed expression profile analysis to
compare U373MG glioblastoma cells infected with wild-type p53
(Ad-p53) with those infected with LacZ (Ad-LacZ) to screen possible
downstream genes that are regulated by p53 and identified more than
50 genes that were likely to be induced by wild-type p53. Among
them, we confirmed that the transcriptional levels of LCE1B and
LCE1C were elevated more than seven-fold higher in the cells
infected with wild-type p53 than those with LacZ (data not shown).
LCE1B and LCE1C belong to the LCE gene cluster containing
multiple well-conserved genes that encode stratum-corneum proteins.
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Figure 1. LCE1 is upregulated by p53. Real-time qPCR analysis of LCE1mRNA expression in U373MG (p53mutant) (A) and H1299 (p53 null)
(B) cells at indicated time points after infection with Ad-p53 or Ad-LacZ at 8 MOIs. (C) Endogenous p53-dependent induction of LCE1mRNA
transcription in p53−/− and p53+/+ HCT116 cells after treatment with adriamycin (1 μg/ml) at various time points. (D) Cells were treated with
UVR at different doses and harvested 36 hours after UVR. β2-Microglobulin was used for the normalization of expression levels.
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chromosome 1q21 and are known to respond “group-wise” to
various environmental stimuli like calcium and UV light [9],
suggesting that other LCE members that were not included in our
microarray might also be regulated by p53. We first compared the
sequence similarity of the LCE1B and LCE1C transcripts with other
members in the LCE cluster (Table W3) and selected genes showing
high similarity (N80%) for further validation by real-time qPCR
because the microarray results might reflect the cross-hybridization of
other LCE members that were possibly induced by p53. Interestingly,
expression levels of LCE1 group genes were significantly increased in
both U373MG (Figure 1A) and H1299 (Figure 1B) cells after 8
MOIs of Ad-p53 infection (Table W4), although the induction levels
are very different. However, other genes in the LCE cluster were not
induced by wild-type p53 introduction. In addition, endogenous
p53, which was activated by adriamycin and UVR, could also induce
expressions of the LCE1 group genes in HCT116 p53+/+ cancer cells
but not in HCT116 p53−/− cancer cells (Figure 1, C and D),
indicating that the LCE1 group genes can respond group-wise to the
genotoxic stress condition in a p53-dependent manner [9].
LCE1 Is a Direct Target of p53
We then attempted to clarify whether LCE1 is directly or indirectly
regulated by p53. First, 11 putative p53BSs of 20 nucleotides with at
least 80% match to the consensus p53-binding sequence (see
Materials and Methods section) were selected from the LCE1 cluster
region (Figure W1A). We then constructed serial reporter vectors
containing each of the 11 predicted p53BSs. Luciferase activity of
p53BS2, p53BS6, and p53BS7 was likely to be enhanced by co-transfection of each luciferase vector and a p53 wild-type expression
vector into U373MG (Figure W1B) and H1299 cells (Figure W1C)
in comparison with those with the mock vector. Hence, these three
p53BSs were further investigated by replacement of critical
nucleotides in the core consensus sequence with other nucleotides
(Figure 2A). As a result, we observed that substitutions in either of
the p53BS2, p53BS6, and p53BS7 sequences significantly dimin-
ished the enhancement of the luciferase activity in both U373MG
and H1299 cells (Figure 2, B and C).These results imply that p53
directly binds to these p53BSs in the LCE1 cluster and regulates
their transcriptions.
We subsequently transfected siRNA targeting p53 or that
commonly targeting LCE1A-F into HCT116 p53+/+ cells and then
the cells were treated with adriamycin. As shown in Figure 2D,
induction of LCE1 genes by adriamycin treatment was significantly
attenuated in the cells transfected with si-p53, also supporting that
LCE1 family genes are p53-direct targets. Additionally, ChIP analysis
showed the direct binding of p53 to the LCE1 cluster region in
HCT116 p53+/+ cells after adriamycin treatment (Figure W2). We
then examined the expression of LCE1F in 82 cancer cell lines by
real-time qPCR (Table W5) and confirmed that LCE1F was
significantly downregulated in p53 mutant cells compared with p53
wild-type cells in colon and lung cancer cell lines (Figure W3). This is
consistent with the induction of LCE1F by p53 in HCT116 colon
and H1299 lung cancer cells as shown in Figure 1.
LCE1F Interacts with PRMT5
To further analyze possible biologic functions of LCE1F in cancer
cells, we constructed an expression vector designed to express full-
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Figure 2. Identification of p53BSs in the LCE1 cluster genes. (A) In the LCE1 cluster genes, we identified 11 potential p53BSs that have at
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into HEK293T cells. After confirmation of the LCE1F protein
expression by Western blot analysis (Figure W4A), we performed
immunocytochemical analysis to examine the subcellular localization
of LCE1F. As shown in Figure W4B, LCE1F was strongly stained in
both nucleus and cytoplasm.
In addition, we attempted to identify the interacting protein(s) of
LCE1F. An HA-tagged LCE1F expression vector or an empty mock
vector was transfected into HEK293T cells, and cell lysates were
immunoprecipitated with anti–HA-conjugated agarose beads. Protein
samples were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and the gel was silver stained. We found a 70-kDa
protein, which was strongly stained only inHA-LCE1F–overexpressing
cells, conducted liquid chromatography–tandem mass spectrometry
analysis of this protein, and identified it to be an arginine
methyltransferase, PRMT5. This result was confirmed using an anti–
PRMT5-specific antibody (Figures 3A andW5). Reversibly, cell lysates
of HA-LCE1F–overexpressed cells were immunoprecipitated with ananti-PRMT5 antibody, and the immunoprecipitates were blotted with
an anti-HA antibody, which also validated the interaction between
LCE1F and PRMT5 (Figure 3B). Moreover, we co-transfected either
FLAG-PRMT5 or FLAG-Mock with HA-LCE1F or HA-Mock, and
cell lysates were immunoprecipitated with an anti-HA antibody
(Figure 3C) or an anti-FLAG antibody (Figure 3D). Subsequent
Western blot analysis clearly indicated the interaction between PRMT5
and LCE1F. These results imply that LCE1F interacts with PRMT5 in
the cells. Interestingly, we confirmed that all LCE1 family proteins
examined could interact with PRMT5 (FigureW6), suggesting that the
interaction with PRMT5 is likely to be a common characteristic among
LCE1 family members.
LCE1F Suppresses PRMT5 Activity
Since PRMT5 was reported to regulate the transcription of various
genes through the methylation of arginine 8 on histone H3 (H3R8),
which is considered to play an important role in human
carcinogenesis [16,20,21], we further investigated the biologic
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expression vector and immunoprecipitated with anti-HA agarose. Samples were immunoblotted with an anti-PRMT5 antibody (Millipore).
(B) HA-LCF1F–transfected HEK293T cells were immunoprecipitated with an anti-PRMT5 antibody or normal rabbit IgG (negative control).
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first performed immunocytochemical analysis and detected co-
localization of LCE1F and PRMT5 in both the nucleus and the
cytoplasm of the HCT116 p53+/+ cells as shown in Figure 4. We thenA B
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DAPI PRMT5
Figure 4. Co-localization of LCE1F and PRMT5. HCT116 p53+/+ c
formaldehyde and stained with an anti-HA antibody (red) and an antiexamined the methylation status of H3R8 after standardizing the
quantity of PRMT5 using the anti-PRMT5 antibody. Using an
antibody for symmetric dimethylation of H3R8 (H3R8me2s), we
conducted Western blot analysis after transfection with siRNAsMergeHA (LCE1F)
DAPI PRMT5
ells were transfected with HA-LCE1F. Cells were fixed by 1.7%
-PRMT5 antibody (green).
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Figure 5. Possible mechanism of LCE1F on regulation of PRMT5 activity. (A) HCT116 p53+/+ cells were transfected with siRNAs targeting
EGFP, p53, or LCE1 for 24 hours and then treated with 1 μg/ml adriamycin. Proteins were extracted from the cells 36 hours after
adriamycin treatment and immunoblotted with anti-p53, anti-H3R8 SDMA (H3R8me2s), or anti–α-tubulin (control) antibodies. (B)
HEK293T cells were co-transfected with either FLAG-Mock or FLAG-PRMT5 and either HA-Mock or HA-LCE1F. Cells were harvested
48 hours after transfection and immunoblotted with anti-H3R8me2s or histone H3 (control) antibodies after histone purification. (C) A
possible model of the network among p53, LCE1F, and PRMT5. p53 induced by DNA damage activates transcription of LCE1F, which
suppresses the PRMT5 methyltransferase activity through their interaction.
662 LCE1, a p53-traget Gene, Regulates PRMT5 Deng et al. Neoplasia Vol. 16, No. 8, 2014targeting Enhanced green fluorescent protein (EGFP), p53, or LCE1
under treatment with adriamycin (Figure 5A) and found that
knockdown of p53 and LCE1 significantly enhanced the methylation
levels of H3R8 in HCT116 p53+/+ cells, compared with the control
cells, suggesting that LCE1 may modulate the PRMT5-dependent
H3R8 methylation. To further validate this result, we co-transfected
either FLAG-PRMT5 or FLAG-Mock and HA-LCE1F or HA-Mock
into HEK293T cells and purified histone proteins from cell lysates.
As shown in Figure 5B, in the presence of LCE1F, H3R8 methylation
by PRMT5 protein was significantly suppressed. Taken together, our
data indicate that LCE1F may negatively regulate PRMT5-
dependent H3R8 methylation through the direct association to
PRMT5.
Discussion
In this study, we showed that LCE1 is a novel p53 target gene and
that the LCE1F protein interacts with the arginine methyltransferase
PRMT5. Through the interaction with PRMT5, LCE1F may
suppress the PRMT5 methylation activity on arginine 8 of histone
H3 (Figure 5C). Since PRMT5 is overexpressed in a wide range of
human cancer and plays a critical role in tumorigenesis through theregulation of histone methylation, we unveiled a novel mechanism of
tumor suppression mediated by p53.
The LCE gene cluster contains multiple conserved genes encoding
stratum-corneum proteins [9,10,12,29]. Our study demonstrated
that most of the members in the LCE1 group are transcriptionally
regulated by the tumor suppressor p53 although the induction levels
varied. Concordantly, LCE1 genes were reported to be significantly
upregulated in response to UVB irradiation of the skin cells [9]. UVR
causesDNAdamage, photoperoxidation of lipids, protein cross-linking,
and isomerization of urocanic acid that lead to immunosuppression,
photo-induced aging and cancer. p53 protein acts as a molecular sensor
for the damages generated by UVR through mediating cell cycle arrest
and apoptosis in damaged keratinocytes [30–34]. Taken together, cells
may possess the function to express LCE1 family genes through p53
activation to eliminate dangerous cells with DNA damages. Impor-
tantly, LCE1 family proteins show a high level of sequence similarity
and LCE1F has more than 90% homology with other members
(LCE1A-E; Table W6). In fact, as mentioned above, we confirmed the
interaction between all of LCE1 proteins examined and PRMT5
(FigureW6). Since the expression of LCE1 cluster genes is regulated by
p53 as a whole (may not be all of the members), this protein family
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function as a tumor suppressor.
We identified PRMT5, a histone methyltransferase, as a key
binding partner of the LCE1 proteins. Current progress of molecular
medicine revealed that the enzymes relevant to histonemethylation play
critical roles in human carcinogenesis [28,35–45]. PRMT5 is one of the
type II arginine methyltransferases, which catalyze the formation of
symmetric dimethylation of arginine residues (SDMA) and regulates
various cellular pathways [16,17,21]. A number of reports described the
importance of this arginine methyltransferase in tumorigenesis
[16,18,21,46–49]. Intriguingly, PRMT5 was reported to interact
with BRG1- and hBRM-based hSWI/SNF chromatin remodelers and
methylate arginine 8 on histone H3 [20]. The H3R8 methylation
mediated by PRMT5-containing BRG1 and hBRM complexes directly
repressed the expression of suppressor of tumorigenicity 7 and nonmeta-
static 23, tumor suppressor genes [20]. This line of pathway seems to be
a key mechanism in the PRMT5-dependent tumorigenesis. Our data
presented here have implied that LCE1, which is regulated by the tumor
suppressor p53, negatively regulates H3R8 methylation mediated by
PRMT5 (Figure 5, A and B), suggesting a new role of p53 in the
regulation of histone modification. Since PRMT5 was reported to
methylate p53 through the direct interaction and this methylation
prevents p53-dependent apoptosis in cancer cells [50], we suggest an
interesting feedback mechanism among p53, LCE1, and PRMT5.
Overall, our study elucidates a novel function of p53 as a tumor
suppressor through the transcriptional regulation of the LCE1 cluster
genes. Further functional analysis may explore the importance of the
LCE1 group proteins as tumor suppressors and the physiological
relevance among p53 downstream genes.
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